DM5167 / Digmbio, Kainos Medicine - LARVOL DELTA

A Phase 1, Dose-Finding Study of the PARP1-Selective Inhibitor DM5167 in Patients with Advanced Solid Tumors (ESMO 2026) - No abstract available

Clinical • Metastases • P1 data • Oncology • Solid Tumor

Preclinical Pharmacokinetics of DM5167, a Novel Selective PARP1 Inhibitor. (PubMed, Pharm Res) - "DM5167 exhibited a favorable pharmacokinetic profile in vivo and in vitro. These findings support its potential for further clinical development and provide valuable insights to guide future preclinical and clinical studies of DM5167 and other PARP inhibitors."

Journal • PK/PD data • Preclinical • Hematological Disorders

Daim Bio selected as KDDF clinical phase 1 support target in 2024 (Hankyung) - "Daim Bio announced on the 14th that it has been selected as a company to receive support for the Phase 1 clinical trial in the 2nd National New Drug Development Project (KDDF) ​​in 2024. Daim Bio plans to receive support for the clinical research and development expenses of a 2nd generation Parp-1 selective inhibitor (DM5167) to evaluate the safety and tolerability of the drug and confirm the maximum tolerated dose (MTD), etc....This government-supported phase 1 clinical trial will be divided into two parts. Part 1 will evaluate the safety and tolerability of the drug mainly targeting patients with HRD mutations including BRCA mutations. In Part 2, an expanded evaluation of the efficacy and safety of DM5167 will be conducted by adding a group of patients with HRD mutation metastatic brain tumors."

Financing • New P1 trial • Brain Cancer • CNS Tumor • Oncology • Solid Tumor • HRD

Dime Bio "2nd generation PARP anti-cancer drug 'DM5167' approved for domestic phase 1 clinical trial" [Google translation] (HIT News) - "Bio venture Dime Bio (CEO Kim Jeong-min) begins clinical trials for new drug candidates targeting solid cancer and brain cancer. Dime Bio announced on the 12th that it has received approval for a phase 1 clinical trial (IND) for the company's second-generation PARP anticancer drug (PARP-1 selective inhibitor) 'DM5167 (development code name)' from the Ministry of Food and Drug Safety....Phase 1 clinical trials will be conducted through oral administration to approximately 30 to 40 patients with triple-negative breast cancer, ovarian cancer, kidney cancer, pancreatic cancer, head and neck cancer, and brain metastasis cancer at three hospitals..."

New P1 trial • Brain Cancer • Head and Neck Cancer • Ovarian Cancer • Pancreatic Cancer • Renal Cell Carcinoma • Triple Negative Breast Cancer

DM5167, a novel selective PARP1 inhibitor, efficiently reduces growth of triple-negative breast cancers (AACR 2023) - "Moreover, DM5167 showed higher selectivity than AZD5305 in the enzymatic assay. In contrast, olaparib failed to reduce xenograft tumors derived from MDA-MB-231 cells. Collectively, these studies present DM5167 as an attractive anti-TNBC drug candidate."

Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HRD • PARP2